The compound "cis"-was first described by Michele Peyrone in 1845, and known for a long time as Peyrone's salt. The structure was deduced by Alfred Werner in 1893. In 1965, Barnett Rosenberg, Van Camp et al. of Michigan State University discovered that electrolysis of platinum electrodes generated a soluble platinum complex which inhibited binary fission in "Escherichia coli" ("E. coli") bacteria. Although bacterial cell growth continued, cell division was arrested, the bacteria growing as filaments up to 300 times their normal length. The octahedral Pt(IV) complex "cis"-[PtCl4(NH3)2, but not the "trans" isomer, was found to be effective at forcing filamentous growth of "E. coli" cells. The square planar Pt(II) complex, "cis"-turned out to be even more effective at forcing filamentous growth. This finding led to the observation that "cis"-[PtCl2(NH3)2 was indeed highly effective at regressing the mass of sarcomas in rats. Confirmation of this discovery, and extension of testing to other tumour cell lines launched the medicinal applications of cisplatin. Cisplatin was approved for use in testicular and ovarian cancers by the U.S. Food and Drug Administration on 19 December 1978. and in the UK (and in several other European countries) in 1979.